{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:39:46Z","timestamp":1775698786258,"version":"3.50.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Unit for Research and Development, Region V\u00e4sternorrland","award":["LVNFOU938547"],"award-info":[{"award-number":["LVNFOU938547"]}]},{"name":"Agreement regarding research and education of doctors, Ume\u00e5 university."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Nephrotic syndrome (NS) is associated with increased risk of venous thromboembolism (VTE). Guidelines suggest prophylactic anticoagulants to patients with high risk of thrombosis and low risk of bleeding, but the evidence behind this is poor. This study aims to investigate the effectiveness and risks of prophylactic anticoagulants (PAC) and investigate risk factors for VTE and bleeding in NS.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A retrospective medical records study including adults with NS, biopsy proven glomerular disease in the county of V\u00e4sternorrland, Sweden. Outcomes were VTE, bleeding and death. Patients divided into PAC- and no PAC group were compared using Fisher\u2019s exact test. Patient time was divided into serum\/plasma(S\/P)-albumin intervals (&lt;20g\/L and \u226520g\/L) and VTE- and bleeding rates were calculated.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>In 95 included NS patients (PAC = 40, no PAC = 55), 7 VTE (7.4%) and 17 bleedings (18%) were found. Outcomes didn\u2019t differ significantly between the PAC and no PAC group. Time with S\/P-albumin &lt;20g\/L conferred higher rates\/100 years of VTE (IRR 21.7 (95%CI 4.5\u2013116.5)) and bleeding (IRR 5.0 (1.4\u201314.7)), compared to time with S\/P-albumin&gt;20g\/L.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Duration of severe hypoalbuminemia (S\/P-albumin &lt;20g\/L) in NS is a risk factor for both VTE and bleeding. There is a need for randomized controlled studies regarding the benefit of PAC in NS as well as risk factors of thrombosis and bleeding in NS.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0255009","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T17:28:50Z","timestamp":1627493330000},"page":"e0255009","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome\u2014A retrospective observational study"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-7215","authenticated-orcid":true,"given":"Frida","family":"Welander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-3099","authenticated-orcid":true,"given":"Henrik","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Em\u00f6ke","family":"Dim\u00e9ny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Sj\u00e4lander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"issue":"17","key":"pone.0255009.ref001","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199804233381707","article-title":"The nephrotic syndrome","volume":"338","author":"SR Orth","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0255009.ref002","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.thromres.2005.03.030","article-title":"Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management","volume":"118","author":"R Singhal","year":"2006","journal-title":"Thromb Res"},{"issue":"8","key":"pone.0255009.ref003","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1681\/ASN.2006111300","article-title":"Prophylactic Anticoagulation in Nephrotic Syndrome: A Clinical Conundrum","volume":"18","author":"RJ Glassock","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"pone.0255009.ref004","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/BF01476873","article-title":"Hypercoagulability in the Nephrotic syndrome","volume":"58","author":"K Andrassy","year":"1980","journal-title":"Klin Wochenschr"},{"issue":"1","key":"pone.0255009.ref005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2141.1982.tb03862.x","article-title":"Relationship between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome","volume":"52","author":"CA Jackson","year":"1982","journal-title":"Br J Haematol"},{"issue":"5","key":"pone.0255009.ref006","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.V52.5.969.969","article-title":"Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome","volume":"52","author":"N Yoshida","year":"1978","journal-title":"Blood"},{"issue":"3","key":"pone.0255009.ref007","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ki.1985.149","article-title":"renal vein thrombosis, and other thrombotic complications of nephrotic syndrome","volume":"28","author":"Llach F. Hypercoagulability","year":"1985","journal-title":"Kidney Int"},{"issue":"1","key":"pone.0255009.ref008","doi-asserted-by":"crossref","first-page":"42","DOI":"10.7326\/0003-4819-107-1-42","article-title":"Protein S deficiency occurs in the nephrotic syndrome","volume":"107","author":"S Vigano-D\u2019Angelo","year":"1987","journal-title":"Ann Intern Med"},{"issue":"3","key":"pone.0255009.ref009","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000185326","article-title":"Intraglomerular deposition of coagulation-fibrinolysis factors and a platelet membrane antigen in various glomerular diseases","volume":"51","author":"F Deguchi","year":"1989","journal-title":"Nephron"},{"issue":"3","key":"pone.0255009.ref010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000187205","article-title":"Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted?","volume":"63","author":"R Bellomo","year":"1993","journal-title":"Nephron"},{"issue":"1","key":"pone.0255009.ref011","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12882-019-1336-8","article-title":"Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications","volume":"20","author":"S Kelddal","year":"2019","journal-title":"BMC Nephrol"},{"issue":"3","key":"pone.0255009.ref012","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2215\/CJN.07190713","article-title":"Retrospective Analysis of a Novel Regimen for the Prevention of Venous Thromboembolism in Nephrotic Syndrome","volume":"9","author":"N Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"pone.0255009.ref013","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000188355","article-title":"Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin","volume":"69","author":"G Rostoker","year":"1995","journal-title":"Nephron"},{"issue":"2","key":"pone.0255009.ref014","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.1994.75","article-title":"Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy","volume":"45","author":"FP Sarasin","year":"1994","journal-title":"Kidney Int"},{"issue":"6","key":"pone.0255009.ref015","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ki.2013.476","article-title":"Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy","volume":"85","author":"T Lee","year":"2014","journal-title":"Kidney Int"},{"key":"pone.0255009.ref016","article-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2012","author":"Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","journal-title":"Kidney Int"},{"issue":"3","key":"pone.0255009.ref017","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis","volume":"62","author":"L Beck","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"pone.0255009.ref018","article-title":"Prophylactic Anticoagulation in Adult Patients with Nephrotic Syndrome","author":"J Gordon-Cappitelli","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"pone.0255009.ref019","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"S Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"4","key":"pone.0255009.ref020","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"3","key":"pone.0255009.ref021","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"FR Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"pone.0255009.ref022","article-title":"OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 3.0.1","author":"SK Dean AG"},{"issue":"3","key":"pone.0255009.ref023","first-page":"232","article-title":"Revised equations for estimating glomerular filtration rate based on the Lund-Malm\u00f6 Study cohort","volume":"71","author":"J Bj\u00f6rk","year":"2011"},{"issue":"1","key":"pone.0255009.ref024","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/ndt\/gfw227","article-title":"Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome","volume":"32","author":"G Gyamlani","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"pone.0255009.ref025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2796.2007.01878.x","article-title":"Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis","volume":"263","author":"A Sj\u00e4lander","year":"2008","journal-title":"J Intern Med"},{"issue":"14","key":"pone.0255009.ref026","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/archinte.167.14.1476","article-title":"Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials","volume":"167","author":"L Wein","year":"2007","journal-title":"Arch Intern Med"},{"key":"pone.0255009.ref027","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.12659\/MSM.912466","article-title":"Clinical Features of Nephrotic Syndrome with Cerebral Hemorrhage","volume":"25","author":"M Yang","year":"2019","journal-title":"Med Sci Monit"},{"issue":"1","key":"pone.0255009.ref028","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/asheducation-2016.1.188","article-title":"Thrombosis and anticoagulation in the setting of renal or liver disease","volume":"2016","author":"C Ribic","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"pone.0255009.ref029","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous Thromboembolism in Patients with Membranous Nephropathy","volume":"7","author":"S Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"pone.0255009.ref030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ekir.2019.12.001","article-title":"A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome","volume":"5","author":"R Lin","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"2","key":"pone.0255009.ref031","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","article-title":"High Absolute Risks and Predictors of Venous and Arterial Thromboembolic Events in Patients With Nephrotic Syndrome","volume":"117","author":"BK Mahmoodi","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"pone.0255009.ref032","first-page":"91","article-title":"A Cohort Study of Incidences and Risk Factors for Thromboembolic Events in Patients with Idiopathic Membranous Nephropathy","volume":"33","author":"PM Zou","year":"2018","journal-title":"Chin Med Sci J"},{"issue":"5","key":"pone.0255009.ref033","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00125-005-1715-5","article-title":"The risk of venous thromboembolism is markedly elevated in patients with diabetes","volume":"48","author":"V Petrauskiene","year":"2005","journal-title":"Diabetologia"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T17:29:18Z","timestamp":1627493358000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255009"}},"subtitle":[],"editor":[{"given":"Hugo","family":"ten Cate","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0255009","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]}}}